Lancet (London, England)

Weekly insulin icodec compared to daily insulin degludec in type 1 diabetes treatment

Updated

Abstract

Among 582 participants, once-weekly insulin icodec demonstrated non-inferiority in reducing HbA1c compared to once-daily insulin degludec at week 26.

  • Estimated mean change in HbA1c at week 26 was -0.47 percentage points for icodec and -0.51 percentage points for degludec.
  • The estimated treatment difference between icodec and degludec was 0.05 percentage points, supporting non-inferiority.
  • The overall rate of combined clinically significant or severe hypoglycaemia was significantly higher with icodec (19.9 events per patient-year) compared to degludec (10.4 events per patient-year).
  • Serious adverse events were reported in 8% of participants receiving icodec and 7% of participants receiving degludec, with one death in the icodec group deemed unlikely related to the trial product.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of interests DR-J reports research income or advisory board honoraria from AstraZeneca, Dexcom, Lilly, Medtronic, Novartis, Novo Nordisk, and Sanofi. TB has received research grants from Abbott, Daiichi Sancho, Eli Lilly, Ono Pharmaceuticals, Terumo, Novartis, Sanwa Kagaku Kenkyusho, and Boehringer Ingelheim and has received honoraria or consulting fees from Tanabe-Mitsubishi, Sumitomo Farma, Eli Lilly, and Novo Nordisk. RC, SE, and MISK are employees of Novo Nordisk and hold stock in Novo Nordisk. CI provided advisory board services for Abbott, Ascensia, Menarini, Novo Nordisk, Roche Diabetes Care Italy, and Senseonics, and received speaker fees from Abbott, Ascensia, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. CM serves or has served on the advisory panel for ActoBio Therapeutics, AstraZeneca, Avotres, Boehringer Ingelheim, Eli Lilly, Imcyse, Insulet, MannKind, Medtronic, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, Vertex, and Zealand Pharma; financial compensation for these activities has been received by KU Leuven (Leuven, Belgium). KU Leuven reports research support for CM from ActoBio Therapeutics, Imcyse, Medtronic, Novo Nordisk, and Sanofi. CM serves or has served on the speakers' bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, and Sanofi; financial compensation for these activities has been received by KU Leuven. JR has served on scientific advisory boards and received honorarium or consulting fees from Applied Therapeutics, Biomea Fusion, Boehringer Ingelheim, Eli Lilly, Hanmi, Intarcia, Novo Nordisk, Oramed, Sanofi, Scholar Rock, Structure Therapeutics, Terns Pharmaceuticals, and Zealand, and has received research support from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi, Novartis, Merck, Novo Nordisk, Oramed, Pfizer, and Sanofi. VW has acted as a consultant for Novo Nordisk and received speaker fees from Novo Nordisk. DCK has acted as a consultant for Better Therapeutics, EOFlow, Integrity, Lifecare, Nevro, Novo Nordisk, Sanofi, and Thirdwayv.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free